EBIT at other companies
Other financials
Where this comes from
Calculated from Trevi Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s EBIT?
- Trevi Therapeutics, Inc. (TRVI) reported EBIT of -$14.91M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s EBIT changed year-over-year?
- Trevi Therapeutics, Inc.'s EBIT decreased by 30.0% year-over-year, from -$11.47M to -$14.91M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s EBIT has grown at a 11.0% compound annual growth rate (CAGR), from -$32.48M to -$49.33M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.